Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Toxicología y Química Legal, Laboratorio de Asesoramiento Toxicológico Analítico (CENATOXA), Ciudad Autónoma de Buenos Aires (CABA), Buenos Aires, Argentina.
Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Toxicología y Química Legal, Laboratorio de Asesoramiento Toxicológico Analítico (CENATOXA), Ciudad Autónoma de Buenos Aires (CABA), Buenos Aires, Argentina.
Forensic Sci Int. 2023 Aug;349:111762. doi: 10.1016/j.forsciint.2023.111762. Epub 2023 Jun 22.
In recent years, the therapeutic use of cannabis products, especially cannabis oils, has increased significantly, due to the pharmacological potential of their cannabinoids, for the treatment of conditions, such as pain management, cancer, and epilepsy. In Argentina, patients with medical prescriptions can access to cannabis oil, through self-cultivation, a third-person (grower or importer), or a civil organization authorized for that purpose. However, these products remain largely unregulated in Argentina, and information available regarding labeling accuracy, especially cannabidiol (CBD)/ Δ-tetrahydrocannabinol (Δ-THC) concentrations are inconsistent or nonexistent, nor long-term product stability, and lot to lot variability. Understanding these properties is fundamental if these products are to be used in patients with a determinate pathology. Therefore, we analyzed commercially available cannabis oils (n: 500) in Argentina for qualitative and quantitative cannabinoids content. In order to provide a detailed overview of their cannabinoids profiles, and determine Δ-THC, CBD, and cannabinol (CBN) concentrations, samples were diluted and analyzed by gas chromatography- mass spectrometry (GC/MS). Most of the samples tested positive for cannabinoids (n: 469) with Δ-THC and CBD as the predominant cannabinoids. Among products tested, only 29.8% (n: 149) gave specific CBD label claims, and testing indicated a CBD tested positive of 70.5% (n: 105). For products (n: 17) with a THC-free label claim, testing indicated 76.5% (n: 13) of Δ-THC positive, and cannabinoids were not detected in four products. Δ-THC concentrations ranged from 0.1 to 143.0 mg/mL, CBD concentrations from 0.1 to 125.3 mg/mL, and CBN concentrations from 0.04 to 60.10 mg/mL; CBN/ Δ-THC ratios ranged from 0.0012 to 2.31, and CBD/ Δ-THC ratios from 0.0008 to 178.87. Furthermore, the (Δ-THC + CBN)/CBD ratio of most samples was greater than one. In summary, our results indicate that cannabis oil products show wide variability in cannabinoids content, purity, and labeling.
近年来,由于大麻素类药物具有药理学潜力,大麻产品(尤其是大麻油)的治疗用途显著增加,可用于治疗疼痛管理、癌症和癫痫等疾病。在阿根廷,有医疗处方的患者可以通过自行种植、第三方(种植者或进口商)或为此目的获得授权的民间组织获取大麻油。然而,这些产品在阿根廷仍然在很大程度上不受监管,关于标签准确性的信息,尤其是大麻二酚(CBD)/Δ-四氢大麻酚(Δ-THC)浓度的信息不一致或不存在,也没有关于长期产品稳定性和批次间变异性的信息。如果要将这些产品用于特定病理的患者,了解这些特性是基础。因此,我们分析了阿根廷市售的 500 种大麻油的定性和定量大麻素含量。为了提供对其大麻素图谱的详细概述,并确定 Δ-THC、CBD 和大麻素(CBN)的浓度,我们将样品稀释后用气相色谱-质谱法(GC/MS)进行分析。测试的大多数样品都呈大麻素阳性(n:469),Δ-THC 和 CBD 是主要的大麻素。在所测试的产品中,只有 29.8%(n:149)符合 CBD 标签声明,测试表明 CBD 阳性率为 70.5%(n:105)。对于有 THC 含量为零标签声明的产品(n:17),测试表明 76.5%(n:13)的 Δ-THC 呈阳性,4 种产品中未检测到大麻素。Δ-THC 浓度范围为 0.1 至 143.0mg/mL,CBD 浓度范围为 0.1 至 125.3mg/mL,CBN 浓度范围为 0.04 至 60.10mg/mL;CBN/Δ-THC 比值范围为 0.0012 至 2.31,CBD/Δ-THC 比值范围为 0.0008 至 178.87。此外,大多数样品的(Δ-THC+CBN)/CBD 比值大于 1。综上所述,我们的研究结果表明,大麻油产品在大麻素含量、纯度和标签方面存在广泛的变异性。